1. Home
  2. INMB vs VIGL Comparison

INMB vs VIGL Comparison

Compare INMB & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INMB
  • VIGL
  • Stock Information
  • Founded
  • INMB 2015
  • VIGL 2020
  • Country
  • INMB United States
  • VIGL United States
  • Employees
  • INMB N/A
  • VIGL N/A
  • Industry
  • INMB Biotechnology: Pharmaceutical Preparations
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • INMB Health Care
  • VIGL Health Care
  • Exchange
  • INMB Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • INMB 112.0M
  • VIGL 95.2M
  • IPO Year
  • INMB 2019
  • VIGL 2022
  • Fundamental
  • Price
  • INMB $4.40
  • VIGL $1.70
  • Analyst Decision
  • INMB Strong Buy
  • VIGL Buy
  • Analyst Count
  • INMB 2
  • VIGL 6
  • Target Price
  • INMB $21.00
  • VIGL $16.60
  • AVG Volume (30 Days)
  • INMB 215.6K
  • VIGL 387.1K
  • Earning Date
  • INMB 10-31-2024
  • VIGL 11-07-2024
  • Dividend Yield
  • INMB N/A
  • VIGL N/A
  • EPS Growth
  • INMB N/A
  • VIGL N/A
  • EPS
  • INMB N/A
  • VIGL N/A
  • Revenue
  • INMB $42,000.00
  • VIGL N/A
  • Revenue This Year
  • INMB N/A
  • VIGL N/A
  • Revenue Next Year
  • INMB N/A
  • VIGL N/A
  • P/E Ratio
  • INMB N/A
  • VIGL N/A
  • Revenue Growth
  • INMB N/A
  • VIGL N/A
  • 52 Week Low
  • INMB $4.32
  • VIGL $1.60
  • 52 Week High
  • INMB $14.74
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • INMB 37.57
  • VIGL 23.30
  • Support Level
  • INMB $4.74
  • VIGL $1.60
  • Resistance Level
  • INMB $5.16
  • VIGL $2.46
  • Average True Range (ATR)
  • INMB 0.38
  • VIGL 0.16
  • MACD
  • INMB -0.05
  • VIGL -0.02
  • Stochastic Oscillator
  • INMB 5.56
  • VIGL 11.63

About INMB INmune Bio Inc. Common stock

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: